EGFR and glioblastoma: Recently, Osimertinib could not only inhibit EGFR-negative glioblastoma patient-derived xenograft (PDX), possibly via regulation of MAPK pathway [47], but also inhibit transcription factor EGFR-TAZ [48], providing a novel insight for drug reuse of EGFR-targeted inhibitors.